Skip to content Skip to footer
Subscribe Now
Viewpoints_Mina Makar
VIEWPOINTS

AstraZeneca at ERA’24: Mina Makar in a Stimulating Conversation with PharmaShots

Shots:  Recently, AstraZeneca presented findings from the real-world IMPACT CKD study, which evaluated the multifaceted impact of CKD on patients, healthcare systems, and broader society, projecting future implications through 2032.  The study emphasizes the importance of mitigating the economic burden on healthcare by implementing early, targeted screening, diagnosis, and treatment for CKD.  In collaboration with…
October 28, 2024

Read more

Akebia
NEWS

Akebia’s Vafseo (Vadadustat) Tablets Gains the US FDA’s Approval to Treat Anemia Due to CKD 

Shots:  The US FDA has approved the company’s Vafseo (vadadustat) tablets as a treatment of anemia associated with chronic kidney disease (CKD) in adults on dialysis for at least 3mos. The company, in collaboration with CSL Vifor, will commercialize Vafseo across the US    The approval was based on the safety and efficacy results from INNO2VATE…
March 27, 2024

Read more

VIEWPOINTS_Anjay Rastogi_2024
VIEWPOINTS

AstraZeneca at ASN 2023: Anjay Rastogi in a Stimulating Conversation with PharmaShots

Shots: Anjay Rastogi, Professor, and Clinical Chief of Nephrology at UCLA, in an insightful conversation with PharmaShots, shares the highlights of AstraZeneca’s presentation at the American Society of Nephrology At ASN 2023, AstraZeneca shares the analysis from the ZORA study, which is a global RWE program that describes the risk of progression to end-stage kidney…
February 12, 2024

Read more